Investigative Ophthalmology & Visual Science Cover Image for Volume 65, Issue 7
June 2024
Volume 65, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2024
Canagliflozin Attenuated p40 Gasdermin D-mediated Retinal Glia-Neuron Crosstalk and Inflammatory Cytokine Release in a Mouse Model of Retinal Vein Occlusion
Author Affiliations & Notes
  • jixian ma
    The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
  • yazhou qin
    The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
  • xuan liu
    The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
  • qiuping liu
    First Affiliated Hospital of University of South China, Hengyang, Hunan, China
  • jingming li
    The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China
  • Footnotes
    Commercial Relationships   jixian ma None; yazhou qin None; xuan liu None; qiuping liu None; jingming li None
  • Footnotes
    Support  NSFC grants 81960177 and 81741058 and a research grant from First Affiliated Hospital of Xi’an Jiaotong University 2021ZXY-10
Investigative Ophthalmology & Visual Science June 2024, Vol.65, 1726. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      jixian ma, yazhou qin, xuan liu, qiuping liu, jingming li; Canagliflozin Attenuated p40 Gasdermin D-mediated Retinal Glia-Neuron Crosstalk and Inflammatory Cytokine Release in a Mouse Model of Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2024;65(7):1726.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Retinal vein occlusion (RVO) is the second most common retinal vascular disease. Blockade of retinal veins initiated an inflammtory response and activated the resident retinal glias, which may further excerbated blood-retinal breakdown and caused irreversible loss of retinal neurons. Pyroptosis is a newly described form of inflammatory programmed cell death that is solely regulated by Gasdermin D, an inflammasome-activated membrane “pore-forming” protein. Canagliflozin, as one of a sodium-glucose cotransporters 2 inhibitors (SGLT-2i), has shown pleiotropic effects against ischemia/reperfusion brain damage. Thus, in the present study, we tested Canagliflozin’s anti-inflammatory and neuroprotective potential against RVO and investigated the underlying mechanisms.

Methods : A mouse model of laser-induced RVO were introduced to C57BL/6J mice.Mice were fed with regular or Canagliflozin-containing chow. Retinal visual dysfunction and vascular dropout was assessed by electroretinogram (ERG) and fundus fluorescein angiography (FFA). Retinal flatmount was utilized to detect activation of microglia cells (MGs) and attenuation of retinal ganglion cells (RGC). The death of RGCs was evaluated with TUNEL staining on retinal cryosections. Retinal distribution and expression the major executors of pyroptosis were determined by immnunostaining or western-blotting analysis.

Results : The retinal a-wave and b-wave amplitude were dramatically reduced and capillary nonperfusion were extensively formed in the lasered mice, which was significantly ameliorated by Canagliflozin.Canagliflozin markedly inhibited laser-induced retinal activation of MGs and massive loss of RGCs.Interestingly, a novel amino-terminal p40 fragment of Gasdermin D were found in retinas of RVO mice, which were mainly expressed by MGs.Furthermore, Canagliflozin intervention significantly reduced the release of IL-1β and IL-18 mediated by p40 gasdermin D and then markedly ameliorated pyroptosis of RGCs.

Conclusions : Taken together, a novel amino-terminal p40 fragment Gasdermin D may mediate glia-neuron crosstalk and be responsible for loss of RGCs in retinas of RVO mice. Canagliflozin protected the retinal neuron damage, at least, partially via attenuating p40 Gasdermin D executed pyroptosis

This abstract was presented at the 2024 ARVO Annual Meeting, held in Seattle, WA, May 5-9, 2024.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×